PedAM
Pediatric Disease Annotations & Medicines
| Disease | hyperphosphatemia |
| Phenotype | C0022658|kidney disease |
| Sentences | 28 |
| PubMedID- 24231489 | Rs has rarely been reported in patients with advanced kidney disease probably due to the pre-existing hyperphosphatemia, hypermagnesemia and hyperkalemia in these patients. |
| PubMedID- 25413959 | Lanthanum carbonate is one of the new phosphate binders used for the treatment of hyperphosphatemia in patients with chronic kidney disease. |
| PubMedID- 20375984 | While these preliminary studies highlight the clinical efficiency and safety of sbr759, its promise of improved therapeutic options for hyperphosphatemia in patients with chronic kidney disease requires further study. |
| PubMedID- 22742885 | Conclusions: second-line treatment with lc is cost-effective in the treatment of end-stage kidney disease in patients with hyperphosphatemia, from a canadian payer perspective. |
| PubMedID- 22798709 | Thus, dietary phosphate restriction can improve aortic endothelial dysfunction in chronic kidney disease with hyperphosphatemia by increase in the activatory phosphorylations of endothelial nitric oxide synthase and akt. |
| PubMedID- 26180236 | Although dietary phosphate restriction is important for treating hyperphosphatemia in patients with chronic kidney disease, it remains unclear whether a low-protein diet (lpd), which contains low phosphate, has beneficial effects on malnutrition, inflammation, and vascular calcification. |
| PubMedID- 24819675 | Managing hyperphosphatemia in patients with late-stage chronic kidney disease requires an individualized approach, involving a combination of adequate dietary advice, phosphate-binder use, and adjustments to dialysis prescription. |
| PubMedID- 25949495 | Lanthanum carbonate (lac) is a non-calcium-based phosphate binder used to treat hyperphosphatemia in patients with chronic kidney disease. |
| PubMedID- 21426511 | Lanthanum carbonate (lc), a newly developed non-calcium-containing phosphate binder, has been shown to possess high phosphate-binding capacity and safety when used for hyperphosphatemia in patients with chronic kidney disease undergoing dialysis. |
| PubMedID- 21324193 | Background: hyperphosphatemia in patients with chronic kidney disease (ckd) contributes to secondary hyperparathyroidism, soft tissue calcification, and increased mortality risk. |
| PubMedID- 26336594 | Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness. |
| PubMedID- 19955298 | Objective: to review the pharmacology, pharmacokinetics, clinical efficacy, safety data, and place in therapy of sevelamer carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease (ckd). |
| PubMedID- 20438515 | Lanthanum carbonate is a non-calcium-based phosphate binder for hyperphosphatemia in patients with chronic kidney disease (ckd). |
| PubMedID- 25815172 | Increased cardiovascular morbidity and mortality has been associated with the hyperphosphatemia seen in patients with end-stage chronic kidney disease (ckd). |
| PubMedID- 24447438 | Dietary trends and management of hyperphosphatemia among patients with chronic kidney disease: an international survey of renal care professionals. |
| PubMedID- 24586576 | In chronic kidney disease patients with hyperphosphatemia) these repairing cells will likely drift toward an osteogenic phenotype, instead of being committed to vsmc differentiation. |
| PubMedID- 25134623 | Calcium-based binders have been a standard treatment for hyperphosphatemia in patients with chronic kidney disease (ckd). |
| PubMedID- 25341358 | Ferric citrate hydrate was recently approved in japan as an oral phosphate binder to be taken with food for the control of hyperphosphatemia in patients with chronic kidney disease (ckd). |
| PubMedID- 22857538 | A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the united kingdom. |
| PubMedID- 25450474 | The purpose of this review is to critically evaluate the studies that have been conducted with this medication and determine where it may fit in the clinician's overall treatment plan for hyperphosphatemia in patients with chronic kidney disease. |
| PubMedID- 20676692 | Calcium (ca)-containing phosphate binders have been recommended for the treatment of hyperphosphatemia in children with chronic kidney disease. |
| PubMedID- 25079863 | Background: lanthanum carbonate (lc), an effective non-calcium phosphate binder is widely used to manage hyperphosphatemia in patients with chronic kidney disease (ckd) on dialysis. |
| PubMedID- 20020207 | Background: the relative effectiveness and safety of sevelamer, a mineral-free phosphate binder, for treatment of hyperphosphatemia in children with chronic kidney disease is uncertain. |
| PubMedID- 24445424 | Purpose of review: the review focuses on the rationale and evidence behind management strategies for hyperphosphatemia in patients with chronic kidney disease (ckd). |
| PubMedID- 25356216 | Severe hyperphosphatemia in a patient with chronic kidney disease and multiple myeloma–to strengthen the case toward renal replacement therapy? |
| PubMedID- 20827429 | In clinical practice, 1,25-(oh)2d3 is widely used in the treatment of hypocalcemia and hyperphosphatemia of patients with chronic kidney disease (ckd). |
| PubMedID- 21354682 | Background: lanthanum carbonate and sevelamer carbonate are noncalcium phosphate binders used to treat hyperphosphatemia in patients with chronic kidney disease. |
| PubMedID- 25017110 | Sbr759 is a novel polynuclear iron(iii) oxide-hydroxide starch.sucrose.carbonate complex being developed for oral use in chronic kidney disease (ckd) patients with hyperphosphatemia on hemodialysis. |
Page: 1